Drug General Information (ID: DDILDPEF1M)
  Drug Name Ibuprofen Drug Info Betrixaban Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Analgesics Anticoagulants/Factor Xa Inhibitors
  Structure

 Mechanism of Ibuprofen-Betrixaban Interaction (Severity Level: Major)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Ibuprofen Betrixaban
      Mechanism Risk of bleeding
Antiplatelet effects 
Risk of bleeding
Anticoagulant 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Ibuprofen and Betrixaban 

Recommended Action
      Management Caution is recommended if betrixaban must be used with other agents that alter hemostasis. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.

References
1 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.